How does Fabhalta (iptacopan) treat paroxysmal nocturnal hemoglobinuria (PNH)?
Fabhalta (iptacopan) treats PNH by blocking the complement system at the C5 step upstream of terminal complement activity. Specifically, it inhibits complement factor B, which reduces formation of the C3/C5 convertase that drives intravascular hemolysis and complement-mediated destruction of red blood cells in PNH. By lowering complement activity, Fabhalta helps reduce hemolysis and helps control anemia-related complications that result from that destruction.
What outcomes does it aim to improve in PNH patients?
Fabhalta is designed to reduce complement-driven breakdown of red blood cells in PNH. In practical terms, that translates into improvement in PNH disease activity markers and symptoms that come from hemolysis, including lower transfusion needs for many patients and improved control of anemia.
How is Fabhalta different from other PNH treatments like eculizumab or ravulizumab?
Unlike C5 inhibitors such as eculizumab and ravulizumab, which block the terminal complement pathway at C5, Fabhalta targets complement factor B earlier in the cascade. That difference in mechanism affects how upstream complement amplification is controlled, rather than directly stopping the formation of the terminal complement complex at C5.
Can Fabhalta be used for patients who are already on other PNH drugs?
Because PNH treatment is individualized, whether patients can transition to or combine therapies depends on prior complement blockade, disease severity, and prescriber judgment. If you’re comparing options or switching, the key practical point is that Fabhalta’s mechanism differs from classic C5 inhibitors, so transition plans must be managed carefully to maintain complement control while avoiding gaps in treatment.
Where can I read more about Fabhalta and its PNH indication?
DrugPatentWatch.com tracks patent and market data for medicines like Fabhalta and can be a useful reference for commercialization and exclusivity context. You can browse Fabhalta coverage here: DrugPatentWatch.com.
Sources cited
- https://www.drugpatentwatch.com/